Price T Rowe Associates Inc Eliem Therapeutics, Inc. Transaction History
Price T Rowe Associates Inc
- $812 Billion
- Q1 2025
A detailed history of Price T Rowe Associates Inc transactions in Eliem Therapeutics, Inc. stock. As of the latest transaction made, Price T Rowe Associates Inc holds 585,728 shares of ELYM stock, worth $2.41 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
585,728
Previous 628,650
6.83%
Holding current value
$2.41 Million
Previous $1.13 Million
36.8%
% of portfolio
0.0%
Previous 0.0%
Shares
3 transactions
Others Institutions Holding ELYM
# of Institutions
72Shares Held
49.8MCall Options Held
0Put Options Held
0-
Ra Capital Management, L.P. Boston, MA31.4MShares$129 Million2.68% of portfolio
-
Cantor Fitzgerald, L. P. New York, NY2MShares$8.22 Million0.18% of portfolio
-
Citigroup Inc1.85MShares$7.6 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.5MShares$6.18 Million0.0% of portfolio
-
Affinity Asset Advisors, LLC New York, NY1.5MShares$6.17 Million0.69% of portfolio
About Eliem Therapeutics, Inc.
- Ticker ELYM
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 26,567,700
- Market Cap $109M
- Description
- Eliem Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing therapies for neuronal excitability disorders to address unmet needs in chronic pain, neuropsychiatry, epilepsy, and other disorders of the peripheral and central nervous systems. Its two lead drug candidates are ETX-810 for chronic pain, which is in Phase II...